The Library
Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease : comprehensive review of preclinical and clinical evidence
Tools
Shabir, Kiran, Brown, James E., Afzal, Islam, Gharanei, Seley, Weickert, Martin O., Barber, Thomas M., Kyrou, Ioannis and Randeva, Harpal S. (2021) Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease : comprehensive review of preclinical and clinical evidence. Cytokine & Growth Factor Reviews, 60 . pp. 120-132. doi:10.1016/j.cytogfr.2021.05.002 ISSN 1359-6101.
|
PDF
WRAP-Asprosin-novel-pleiotropic-adipokine-implicated-fasting-obesity-cardio-metabolic-disease-2021.pdf - Accepted Version - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (769Kb) | Preview |
Official URL: https://doi.org/10.1016/j.cytogfr.2021.05.002
Abstract
White adipose tissue is a dynamic endocrine organ that releases an array of adipokines, which play a key role in regulating metabolic homeostasis and multiple other physiological processes. An altered adipokine secretion profile from adipose tissue depots frequently characterizes obesity and related cardio-metabolic diseases. Asprosin is a recently discovered adipokine that is released in response to fasting. Following secretion, asprosin acts - via an olfactory G-protein coupled receptor and potentially via other unknown receptor(s) - on hepatocytes and agouti-related peptide-expressing neurons in the central nervous system to stimulate glucose secretion and promote appetite, respectively. A growing body of both in vitro and in vivo studies have shown asprosin to exert a number of effects on different metabolic tissues. Indeed, asprosin can attenuate insulin signalling and promote insulin resistance in skeletal muscle by increasing inflammation and endoplasmic reticulum stress. Interestingly, asprosin may also play a protective role in cardiomyocytes that are exposed to hypoxic conditions. Moreover, clinical studies have reported elevated circulating asprosin levels in obesity, type 2 diabetes and other obesity-related cardio-metabolic diseases, with significant associations to clinically relevant parameters. Understanding the spectrum of the effects of this novel adipokine is essential in order to determine its physiologic role and its significance as a potential therapeutic target and/or a biomarker of cardio-metabolic disease. The present review offers a comprehensive overview of the published literature on asprosin, including both clinical and preclinical studies, focusing on its role in metabolism and cardio-metabolic disease.
Item Type: | Journal Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QP Physiology Q Science > QR Microbiology > QR180 Immunology R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||
Library of Congress Subject Headings (LCSH): | Cytokines, Adipose tissues, Fasting -- Health aspects, Obesity -- Risk factors, Non-insulin-dependent diabetes -- Risk factors, Cardiovascular system -- Diseases -- Risk factors | ||||||||
Journal or Publication Title: | Cytokine & Growth Factor Reviews | ||||||||
Publisher: | Elsevier Ltd | ||||||||
ISSN: | 1359-6101 | ||||||||
Official Date: | August 2021 | ||||||||
Dates: |
|
||||||||
Volume: | 60 | ||||||||
Page Range: | pp. 120-132 | ||||||||
DOI: | 10.1016/j.cytogfr.2021.05.002 | ||||||||
Status: | Peer Reviewed | ||||||||
Publication Status: | Published | ||||||||
Access rights to Published version: | Restricted or Subscription Access | ||||||||
Date of first compliant deposit: | 26 July 2021 | ||||||||
Date of first compliant Open Access: | 28 May 2022 | ||||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year